SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-012539
Filing Date
2017-11-07
Accepted
2017-11-07 17:16:45
Documents
50
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 364501
2 image_001.jpg GRAPHIC 8812
3 ex31-1.htm EX-31.1 16110
4 ex32-1.htm EX-32.1 7894
  Complete submission text file 0001493152-17-012539.txt   2740162

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE endv-20170930.xml EX-101.INS 416818
6 XBRL SCHEMA FILE endv-20170930.xsd EX-101.SCH 38549
7 XBRL CALCULATION FILE endv-20170930_cal.xml EX-101.CAL 39027
8 XBRL DEFINITION FILE endv-20170930_def.xml EX-101.DEF 160654
9 XBRL LABEL FILE endv-20170930_lab.xml EX-101.LAB 287862
10 XBRL PRESENTATION FILE endv-20170930_pre.xml EX-101.PRE 226125
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 171184387
SIC: 2834 Pharmaceutical Preparations